Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
10 August 2021 - 9:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16 of
the Securities Exchange Act of 1934
For the month of August 2021
Commission File Number: 001-40299
Achilles Therapeutics plc
(Exact name of registrant as specified in its charter)
245
Hammersmith Road
London W6 8PW
United Kingdom
Tel: +44
(0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal
Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Achilles Reports Second Quarter 2021 Financial Results and Recent Business Highlights
On August 10, 2021, Achilles Therapeutics plc (Achilles or the Company) issued a press release, a
copy of which is furnished as Exhibit 99.1 to this Current Report on Form 6-K, reporting its financial results for the three and six month periods ended June 30, 2021 and providing an update on recent
business highlights. Furnished (i) as Exhibit 99.2 to this Current Report on Form 6-K are the Companys unaudited consolidated financial statements for the three and six month periods ended
June 30, 2021 and (ii) as Exhibit 99.3 to this Current Report on Form 6-K is the Managements Discussion and Analysis of Financial Condition and Results of Operations for the three and six month
periods ended June 30, 2021.
The statements contained in this Achilles Therapeutics Reports Second Quarter
2021 Financial Results and Recent Business Highlights section of this Current Report on Form 6-K and the information contained in Exhibits 99.1 and 99.2 shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and is not incorporated by reference into any of the Companys filings under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ACHILLES THERAPEUTICS PLC
|
|
|
|
|
Date: August 10, 2021
|
|
|
|
By:
|
|
/s/ Robert Coutts
|
|
|
|
|
|
|
Robert Coutts
|
|
|
|
|
|
|
Chief Financial Officer
|
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Oct 2023 to Oct 2024